Market Cap 545.74B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.51
Forward PE 19.94
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 10,141,600
Avg Vol 7,722,766
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 73%
Beta 0.27
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
oceanviewhi
oceanviewhi May. 19 at 11:55 AM
$IBRX Clinical and Commercial Showdown: Why Anktiva + BCG "Blows Away" J&J’s TAR-200 the head-to-head data comparing ImmunityBio’s ($IBRX) Anktiva platform to Johnson & Johnson's ($JNJ) TAR-200 is the ultimate valuation driver. J&J has positioned TAR-200 (an intravesical drug-delivery system releasing gemcitabine) as the primary threat to Anktiva’s market share. However, the latest clinical comparative data released at AUA 2026 and summarized this morning proves that Anktiva's "living vaccine" approach completely outclasses J&J’s mechanical device on every major clinical metric. 1. Durability of Response (DOR): The Ultimate Clinical Decider The single most important metric in bladder cancer is how long a patient remains cancer-free. The Anktiva Standard: The QUILT-3.032 trial demonstrated a median Duration of Response (DOR) of 47.0 months in patients who achieved a Complete Response (CR). This is an unprecedented timeline that allows patients to keep their bladders for years.
0 · Reply
CFJHauser
CFJHauser May. 19 at 11:51 AM
0 · Reply
ReaLiLJ
ReaLiLJ May. 19 at 10:54 AM
$GOVX $SBFM $JNJ $MRK https://www.nbcnews.com/world/africa/ebola-outbreak-deaths-rise-scale-speed-concerns-who-congo-uganda-rcna345833 https://www.nytimes.com/2026/05/19/world/africa/ebola-outbreak-deaths-congo-who.html https://www.reuters.com/business/healthcare-pharmaceuticals/who-chief-concerned-speed-scale-ebola-outbreak-cases-rise-2026-05-19/
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 19 at 9:35 AM
$JNJ favors rally from daily #Bluebox area targeting 259.3, while holds above 220.37 low It favors rally in (1) of ((5)) and expect continuation within January-2025 bull run explained in article https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #JNJ
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 19 at 1:50 AM
$KAPA my guess $JNJ because ERLEADA (apalutamide) works but suffers resistance. Kairos is testing ENV105 with it and ZYTIGA. But could also be $PFE with XTANDI. Those would be my guesses
0 · Reply
ReaLiLJ
ReaLiLJ May. 18 at 7:55 PM
$GOVX https://www.bbc.com/news/articles/cq6pz60p996o $JNJ $MRK
0 · Reply
SuperGreenToday
SuperGreenToday May. 18 at 7:00 PM
$JNJ Share Price: $228.50 Contract Selected: Jun 12, 2026 $230 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.53 – $7.98 Potential Upside: 75% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
falcon_trader11
falcon_trader11 May. 18 at 6:15 PM
Not many small biotech names can reference relationships tied to $JNJ and $IDXX . $HYFT ecosystem keeps getting more interesting.
0 · Reply
trenddetector
trenddetector May. 18 at 3:13 PM
$JNJ Multiple myeloma is one of those diagnoses that can feel like the floor just dropped out. Patients prescribed Darzalex are often already deep into their treatment journey and looking for any edge they can find. YourCancerPath.com gives myeloma patients a free, anonymous place to understand their options — Darzalex included — without having to dig through dense medical journals or pay for a navigator. If you have a friend or family member fighting multiple myeloma, please pass this along. Sometimes just knowing there's a clear resource makes the next step feel possible. 🔗 YourCancerPath.com #multiplemyeloma #Darzalex #JNJ #YourCancerPath
0 · Reply
CapitalMonk
CapitalMonk May. 18 at 2:17 PM
$JNJ Price: $226.30 (-0.18%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.79% RSI: 47.4 | Momentum: Moderate Volume: -89.5% vs avg Volatility: 1.26% Support: $220.37 | Resistance: $232.14 Sourch: http://marketbaubles.com/
0 · Reply
Latest News on JNJ
CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 14 days ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 17 days ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 21 days ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 22 days ago

J&J sees AI halving the time to generate drug development leads


Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 26 days ago

Johnson & Johnson Transcript: AGM 2026


Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 5 weeks ago

Johnson & Johnson CFO on the company's robotic surgical system


Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings Call Transcript: Q1 2026


Johnson & Johnson Earnings release: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings release: Q1 2026


Johnson & Johnson Slides: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Slides: Q1 2026


Johnson & Johnson Quarterly report: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Quarterly report: Q1 2026


J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 5 weeks ago

J&J raises guidance for 2026 on strong start to the year


Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook


J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 5 weeks ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength


The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 2 months ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX


US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 2 months ago

US FDA approves J&J's oral psoriasis pill


oceanviewhi
oceanviewhi May. 19 at 11:55 AM
$IBRX Clinical and Commercial Showdown: Why Anktiva + BCG "Blows Away" J&J’s TAR-200 the head-to-head data comparing ImmunityBio’s ($IBRX) Anktiva platform to Johnson & Johnson's ($JNJ) TAR-200 is the ultimate valuation driver. J&J has positioned TAR-200 (an intravesical drug-delivery system releasing gemcitabine) as the primary threat to Anktiva’s market share. However, the latest clinical comparative data released at AUA 2026 and summarized this morning proves that Anktiva's "living vaccine" approach completely outclasses J&J’s mechanical device on every major clinical metric. 1. Durability of Response (DOR): The Ultimate Clinical Decider The single most important metric in bladder cancer is how long a patient remains cancer-free. The Anktiva Standard: The QUILT-3.032 trial demonstrated a median Duration of Response (DOR) of 47.0 months in patients who achieved a Complete Response (CR). This is an unprecedented timeline that allows patients to keep their bladders for years.
0 · Reply
CFJHauser
CFJHauser May. 19 at 11:51 AM
0 · Reply
ReaLiLJ
ReaLiLJ May. 19 at 10:54 AM
$GOVX $SBFM $JNJ $MRK https://www.nbcnews.com/world/africa/ebola-outbreak-deaths-rise-scale-speed-concerns-who-congo-uganda-rcna345833 https://www.nytimes.com/2026/05/19/world/africa/ebola-outbreak-deaths-congo-who.html https://www.reuters.com/business/healthcare-pharmaceuticals/who-chief-concerned-speed-scale-ebola-outbreak-cases-rise-2026-05-19/
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 19 at 9:35 AM
$JNJ favors rally from daily #Bluebox area targeting 259.3, while holds above 220.37 low It favors rally in (1) of ((5)) and expect continuation within January-2025 bull run explained in article https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #JNJ
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 19 at 1:50 AM
$KAPA my guess $JNJ because ERLEADA (apalutamide) works but suffers resistance. Kairos is testing ENV105 with it and ZYTIGA. But could also be $PFE with XTANDI. Those would be my guesses
0 · Reply
ReaLiLJ
ReaLiLJ May. 18 at 7:55 PM
$GOVX https://www.bbc.com/news/articles/cq6pz60p996o $JNJ $MRK
0 · Reply
SuperGreenToday
SuperGreenToday May. 18 at 7:00 PM
$JNJ Share Price: $228.50 Contract Selected: Jun 12, 2026 $230 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.53 – $7.98 Potential Upside: 75% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
falcon_trader11
falcon_trader11 May. 18 at 6:15 PM
Not many small biotech names can reference relationships tied to $JNJ and $IDXX . $HYFT ecosystem keeps getting more interesting.
0 · Reply
trenddetector
trenddetector May. 18 at 3:13 PM
$JNJ Multiple myeloma is one of those diagnoses that can feel like the floor just dropped out. Patients prescribed Darzalex are often already deep into their treatment journey and looking for any edge they can find. YourCancerPath.com gives myeloma patients a free, anonymous place to understand their options — Darzalex included — without having to dig through dense medical journals or pay for a navigator. If you have a friend or family member fighting multiple myeloma, please pass this along. Sometimes just knowing there's a clear resource makes the next step feel possible. 🔗 YourCancerPath.com #multiplemyeloma #Darzalex #JNJ #YourCancerPath
0 · Reply
CapitalMonk
CapitalMonk May. 18 at 2:17 PM
$JNJ Price: $226.30 (-0.18%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.79% RSI: 47.4 | Momentum: Moderate Volume: -89.5% vs avg Volatility: 1.26% Support: $220.37 | Resistance: $232.14 Sourch: http://marketbaubles.com/
0 · Reply
Diefreeandsell
Diefreeandsell May. 18 at 1:25 PM
$IBRX $JNJ $MRK $XBI $IBB We already knew this, didn't we? The general consensus emerging from the comparison data is that if the BCG supply chain holds, Anktiva + BCG delivers superior multi-year durability and a less invasive administration cycle compared to the mechanical maintenance required by TAR-200, strongly positioning it to command the standard of care for long-term disease-free survival. SOC SOC!
0 · Reply
Diefreeandsell
Diefreeandsell May. 18 at 12:13 PM
$IBRX I assume this will be mentioned in40 mins during caparison data presentation: $JNJ TAR-200: The durability drops off a bit quicker over time compared to Anktiva, tracking closer to a $46% CR rate at 12 months and $42% at 24 months. It requires placing and later retrieving a physical drug-delivery system from the bladder via a cystoscopic office procedure every few weeks. Anktiva is a straightforward intravesical instillation (catheter fluid), but it must be administered alongside BCG. If a urologist has a stable supply of BCG, Anktiva + BCG is highly favored for long-term, multi-year disease-free survival and true bladder preservation. So they are solving the BCG shortage problem at least 2 ways and will become the SOC! Thanks for nothing $MRK !
1 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 18 at 11:30 AM
$JNJ favors rally above 259.3 or higher, while holding the pullback above 220.37 low It expected double correction, which ended at 220.37 in daily #Bluebox area. Above there, it favors higher in next leg within January-2025 rally or at least 3 swing bounce. https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #JNJ
0 · Reply
Diefreeandsell
Diefreeandsell May. 18 at 9:56 AM
$IBRX Good morning all!! is it 8:52 yet ? can’t wait for the Indirect Treatment Comparison (ITC) data. Crazy that a co feels that confident to compare $JNJ’s tar200 against anktiva! Who wants to put tar in their body, just not safe !
2 · Reply
clan
clan May. 16 at 12:00 PM
$JNJ $IBB For abt $40B, might JNJ swoop in and acquire both $UTHR and $MNKD at the same time? It would be for the good of all Mannkind.
0 · Reply
Quantumup
Quantumup May. 15 at 6:14 PM
BofA⬆️ $CGON's PT to $87 after⬆️its peak penetration in the BCG-Exposed setting, while reiterating Buy and saying—cohort CX data reinforces widespread value oppty. $URGN TARA MRK IBRX TYRA $JNJ Here's what BofA went on to say: https://x.com/Quantumup1/status/2055350522350080153?s=20
0 · Reply
Diefreeandsell
Diefreeandsell May. 15 at 5:32 PM
$IBRX $XBI $IBB $TNA $JNJ Forgot to include this ubiquitous song from a fav band o mine. ANKTIVA is a PIPELINE in A DRUG! https://www.youtube.com/watch?v=HrxX9TBj2zY
1 · Reply
Suite510
Suite510 May. 15 at 4:29 PM
$ABT $JNJ $KVUE $SPX JNJ is a ticking bomb, 30B to 50B talc liability upcoming, there getting slammed in LA Court this week 😂 66,000 plaintiffs will finally get there justice after years of delays May 14, 2026 Human Reproduction Proves Talc Can Reach Ovaries, Jury Told A medical oncologist on Thursday told a Los Angeles bellwether jury considering claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that the female reproductive system is an "open" system where talc can migrate to the ovaries, and that "we wouldn't exist" if that was not!
1 · Reply
Diefreeandsell
Diefreeandsell May. 15 at 1:08 PM
$IBRX $XBI $JNJ $MRK $TNA Agreed. Ever since the FDA warning BS letter in March the stock has been beaten down, all you have to do is look at charts, lost about 26% and these clowns can't see that it's being supported now and is climbing a wall of worry. The flush they expect to happen is already behind us. Yet these clowns still expect a sell the news event but don't understand that only happens when a stock is overextended and trading at highs headed into a catalyst full AUA weekend. The weak hands are gone, Tute support is strong and it's been basically going sideways to up since March. The fact that it held $7.42 and has clawed back to $8.15 past all the BS lawsuit advertising noise is super supportive and now the focusi is on the AUA 2026 data/presentations. The fact that they are presenting comparative data MONDAY MORNING(Pre-MKT) specifically is a risky move. You don't usually invite a head-to-head comparison unless your data can win on efficacy, duration, and safety.🥁
1 · Reply
Quantumup
Quantumup May. 15 at 11:59 AM
Cantor⬆️ $GHRS's PT to $35 from $25, reiterated Overweight and said: With a $1.5B mkt cap, we believe GHRS trades at <1x peak achievable sales for '001. $JNJ HELP ATAI CYBN DFTX $CMPS Canaccord Genuity y'day reiterated GH Research Buy; $39 and said: GHRS reported its 1Q26 results earlier today (5/14). Operating expenses of $18.7MN were essentially in line with our $19.0MN estimate. Here's what Canaccord Genuity went on to say: https://x.com/Quantumup1/status/2055256016053272620?s=20
1 · Reply
Quantumup
Quantumup May. 15 at 11:28 AM
Guggenheim⬆️ $ALMS's PT to $34 and reiterated at Buy after the company's 1Q26 earnings release. $JNJ - $PTGX ORKA TAK BMY ABBV ARQT MLTX Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2055248200810836423?s=20
0 · Reply
Quantumup
Quantumup May. 15 at 10:44 AM
Goldman Sachs➡️ $ORIC from Early-Stage Biotech to a Buy rating and a $15 PT. $PFE IPSEY VIR CADL BAYRY NVS $JNJ Here's what Goldman Sachs said in its note to investors: https://x.com/Quantumup1/status/2055237364960641244?s=20
0 · Reply